Glaxosmithkline Stock News

Sanofi SA (NASDAQ: SNY ) and GlaxoSmithKline plc (NYSE: GSK ) are seeking regulatory approval for their COVID-19 vaccine to be used as a booster, as well as a standalone two-dose shot. In two separate trials, the companies said their adjuvanted protein-based vaccine demonstrated "universal ability" to boost neutralizing antibodies whether following mRNA or adenovirus shots, as well as 57.9% efficacy against any symptomatic COVID-19 disease. Protection against moderate or severe disease was better at 75%, yet higher … Full story available on Benzinga.com

Drugmakers Sanofi and GlaxoSmithKline say they will seek regulatory approval for a new COVID-19 vaccine after human trials showed it provided a high level of protection against the disease

LONDON (AP) — Drugmakers Sanofi and GlaxoSmithKline said Wednesday they will seek regulatory approval for a new COVID-19 vaccine after…

Sanofi and GlaxoSmithKline are seeking regulatory approval for their Covid-19 vaccine to be used as a booster, as well as a standalone two-dose shot.

Sanofi and GlaxoSmithKline Plc, the pharma giants that stumbled in the race to develop a Covid-19 shot, found their vaccine protects against severe disease and hospitalization and will submit data to regulators for clearance.

Sanofi (NASDAQ: SNY) and GlaxoSmithKline plc (NYSE: GSK) report intent to submit data from both their booster and Phase 3 efficacy trials as the basis for regulatory applications for a COVID-19 vaccine. The Sanofi-GSK booster vaccine has provided a significant increase in neutralizing antibodies of 18- to 30-fold across vaccine platforms and age groups. Thomas Triomphe, Executive Vice President, Sanofi Vaccines, said: Were very pleased with these data, which confirm our strong science and the benefits of our COVID-19 vaccine. The Sanofi-GSK vaccine demonstrates a universal ability to boost all platforms and across all ages. We also observed robust efficacy of the vaccine as a primary series in todays challenging epidemiological environment. No other global Phase 3 efficacy study has been undertaken during this period with so many variants of concern, including Omicron, and these efficacy data are similar to the recent clinical data from authorized vaccines.

Sanofi (SNY) and GlaxoSmithKline (GSK) are planning to seek regulatory authorization for a COVID-19 vaccine.The companies intend to submit data from their booster and phase 3

British drugs giant GlaxoSmithKline said Tuesday that its consumer healthcare division will be spun off later this year under the name Haleon

GlaxoSmithKline(GSK) announced that its consumer healthcare division partly owned by Pfizer (PFE) would be called Haleon after its spinoff from the main business. Read more.

THE new consumer healthcare company to be spun out from GlaxoSmithKline will be named Haleon, it was announced today.

THE new consumer healthcare company to be spun out from GlaxoSmithKline will be named Haleon, it was announced today.

Sanofi found using ticker (SNY) now have 4 analysts covering the stock with the consensus suggesting a rating of ''Strong_Buy''. The target price ranges between 68.5 and 58 calculating the average target price we see 63.63. With the stocks previous close at 52.87 this would indicate that there is a potential upside of 20.4%. The 50 day moving average now sits at 51.1 and the 200 moving average now moves to 50.97. The company has a market cap of $132,438m. Find out more information at: https://www.sanofi.com [stock_market_widget type="chart" template="basic" color="green" assets=SNY" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $159,391m based on the market concensus. Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products.

Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front, the Food and Drug Administration approved Agios Pharmaceuticals, Inc.''s (NASDAQ: AGIO ) mitapivat for treating pyruvate kinase deficiency, a rare, inherited metabolic disorder. Avenue Therapeutics, Inc. (NASDAQ: ATXI ) stock tumbled close to 60% after an FDA panel found that data included in the company''s new drug application for pain drug tramadol was inadequate to support approval. GlaxoSmithKline plc (NYSE: GSK ) and Sanofi (NASDAQ: SNY )- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) suffered setbacks after their respective late-stage studies of respiratory syncytial vaccine candidate in pregnant women and Dupixent as a treatment option for skin rash had to be halted. Here are the key catalysts for the unfolding week: Conferences 49th Annual Scientific and Technology Meeting of the American Auditory Society, AAS (hybrid event) Feb. 24-27, in Scottsdale, Arizona & online Multidisciplinary Head and Neck Cancers Symposium (virtual event): Feb. 24-27, in Phoenix, Arizona & online International Society of Nephrology''s World Congress of Nephrology, or WCN, 2022 (hybrid event): Feb. 24-27, in Kuala Lumpur & online PDUFA Dates The FDA has set a PDUFA date of Friday, Feb. 25, for its new drug application for Reata Pharmaceuticals, Inc.''s (NASDAQ: RETA ) Bardoxolone.

GlaxoSmithKline is pausing trials of an respiratory syncytial virus vaccine in pregnant women. Sanofi is halting a trial of its drug Dupixent as a treatment…

GlaxoSmithKline plc (NYSE: GSK ) has paused a late-stage trial of its respiratory syncytial virus (RSV) vaccine candidate in pregnant women based on safety recommendations from an independent committee. GSK did not explain why it paused the phase 3 GRACE trial and two other studies. The Company said that halt doesn''t apply to its AReSVi 006 phase 3 trial of the jab in … Full story available on Benzinga.com